Substrate mapping was developed to treat poorly tolerated, infarct-related ventricular tachycardias (VT). The concept of substrate mapping was based on 30-year-old data derived from surgical and percutaneous mapping during sinus rhythm and VT, which demonstrated specific electrograms (EGMs) that characterized the "arrhythmogenic substrate" of VT. Characteristics of these EGMs included low-voltage, fractionation, long duration, split signals, and isolated late potentials as well as adjacent early and late activation.
Introduction of electroanatomical mapping (EAM) systems during the mid-1990s has allowed investigators to record EGMs in three dimensions and to identify sites assumed to represent the central common pathway (isthmus) during reentrant VTs. However, currently used substrate mapping techniques are based on assumptions that have not been validated, which limits our ability to accurately define the true arrhythmogenic substrate.
These assumptions include:
• Reentrant circuits are produced by fixed barriers of immutable, "inexcitable" scar tissue; hence, barriers forming the isthmus during VT are present during sinus rhythm
• Low-voltage amplitude (≤ 0.5 mV) implies dense "inexcitable" scar, and the bipolar amplitude is a reflection of the underlying tissue
• Isthmuses identified in patients with tolerated VTs using entrainment mapping are both valid and provide an accurate depiction of isthmuses in less hemodynamically tolerated VTs
• Current mapping tools and methods can delineate specific electrophysiologic features that will determine the barriers forming channels during reentrant VTs Despite acute success of ablation strategies based on the assumptions above, the VT recurrence rate at one year remains unacceptably high, ranging 50-60%. In addition, recent experimental and human data using high-resolution mapping with very small electrodes cast doubt on the validity of those assumptions.
These data call for re-evaluation of substrate-mapping techniques to characterize the arrhythmogenic substrate of postinfarction VT. Many of the limitations of current recording techniques can be overcome with the use of new catheters with small electrodes and closer interelectrode spacing, which markedly improves resolution. Standardization of recording techniques including electrode size, interelectrode spacing, tissue contact, catheter orientation and wavefront activation must be taken into consideration.
No limitations were identified by the author in this publication. CONTRAINDICATIONS There are no known contraindications.
WARNINGS AND PRECAUTIONS
The use of the Rhythmia Mapping System in conjunction with radio frequency ablation and other medical devices, as a part of the diagnosis and treatment of cardiac arrhythmias, may pose a risk of adverse events, such as cardiac perforation and arrhythmias (new and/or exacerbation of existing arrhythmias) that may require additional intervention. Do not operate the Rhythmia Mapping System near flammable anesthetics. System operation near flammable anesthetics may cause an explosion that could cause injury or death to the patient or user. All devices that are connected to the Rhythmia Mapping System must meet IEC 60601-1 requirements and any other relevant safety standards. When connected to other devices, the combined systems' configuration must meet the IEC 60601-1-1 safety standards. The use of the Rhythmia Mapping System with accessories and devices that do not comply with relevant standards may reduce the safety of the system, cause equipment damage or system malfunction, or harm to the patient or user. Only stimulators that are certified for IEC 60601 should be used with the Rhythmia Mapping System. Do not connect life-sustaining pacing through the Rhythmia Mapping System. The system is not intended to provide life-sustaining therapy and should not be used as such. In case of need for emergency pacing, or any failure of stimulator routing, directly connect the desired paced channel to the stimulator. The Rhythmia Mapping System is only designed to route the stimulation signal to the desired channel. To start or stop stimulation, always use the controls on the external stimulator. Use the Rhythmia Mapping System only with one of the following RF ablation generators: Maestro 3000 ™ , Stockert ™ , or IBI ™ . Do not use the system with other RF ablation generators. Compatibility with other RF ablation generators has not been demonstrated. Do not apply RF energy larger than 150W to ablation catheters that are connected to the Maestro 3000 RF generator and the Rhythmia Mapping System. Do not apply RF energy larger than 70W to ablation catheters that are connected to the Stockert RF generator and the Rhythmia Mapping System. Do not apply RF energy larger than 50W to ablation catheters that are connected to the IBI RF generator and the Rhythmia Mapping System. To reduce the risk of electric shock or equipment damage, do not clean the Rhythmia Mapping System when it is plugged in, turned on, or connected to a patient. Cleaning the system while it is in use and connected to a power source may cause an electrical shock that could cause injury or death to the patient or user. To reduce the risk of electric shock, assure that any ECG cables and electrodes are not in contact with any other conductive parts, including ground. To reduce the risk of electric shock during defibrillation, assure that the exposed connector tips on the ECG output box are covered at all times with the protective, non-conductive material provided with the ECG output boxes. Do not use the ECG output box if the protective cover is damaged (see ECG Output Box). The system generates electrical impedance fields as part of its normal operation. Do not use other systems that also generate electrical impedance fields in the same procedure, as this may interfere with the system's normal operation and reduce the quality of catheter localization, and signals. Magnetic Localization System Do not operate the Localization Generator within 200 mm of installed cardiac implantable electronic devices (CIEDs). Doing so may affect pacing, temporarily suspend tachycardia therapy delivery, or lead to patient discomfort. Signal Station To minimize the risk of electric shock, connect the Signal Station only to supply mains with a protective ground (earth) connection. Use only a functioning, properly tested supply main with protective ground (earth) to power the Rhythmia Mapping System. The use of a faulty, ungrounded supply main increases the risk of electrical shock and system malfunction. To minimize the risk of electric shock, prior to using the Rhythmia Prior to using the Rhythmia Mapping System, inspect all external connections and cable connectors. Make sure all connections are secure. Tighten any loose connections prior to using the system. Do not use excessive force when connecting or disconnecting cable connectors. Excessive force can damage the connectors, which may cause system malfunction. Do not kink or sharply bend cables. Kinks and sharp bends can damage the cables, which may cause system malfunction. To minimize the risk of damage, store unused system cables in a clean, dry, and secure location, consistent with storage guidelines (see Equipment Storage & Transporting in the DFU). Electrical Never use ungrounded electrical outlets to power any system components. Do not use extension cords or adapters for ungrounded outlets. Using ungrounded outlets, extension cords, or adapters may cause equipment damage, system failure or malfunction. Body Surface Electrodes Use care when attaching the body surface electrodes to lead connectors. To minimize the risk of electric shock, make sure that electrodes and lead connectors do not contact one another or contact ground. To prevent low quality signals from body surface electrodes, properly prepare the skin prior to attaching the electrodes. 
